In brief: MediVac, C3, Premier Bionics
Thursday, 20 October, 2005
Bob Atwill will join MediVac (ASX:MDV) as a consultant to assist in the commercialisation of the company's MetaMizer series II. Atwill was formerly sales and marketing director of London Stock Exchange listed orthopaedic company Corin Group.
Clinical Cell Culture (ASX:CCE, C3) has appointed distributors for its autologous cell harvesting device ReCell in Chile and Brazil, having secured market approval in Chile and with regulatory approval in Brazil expected in the next 6 to 12 months. This follows ReCell's approval for sale in Argentina. The company expects US FDA approval for ReCell by December 31.
Premier Bionics< (ASX:PBI) has appointed London-based Duncan Clegg as a non-executive director. Clegg is the chairman of specialist materials manufacturer Low & Bonar, listed on the London stock exchange, and a former executive director of international merchant banking group Lazard Brothers & Co. He is also vice chairman of the Port of London Authority and a member of the Cook Society, which encourages business connections between Australia and the UK.
More effective antibiotic found for Lyme disease
Researchers have found that piperacillin, an antibiotic in the same class as penicillin,...
Why do our waistlines expand in middle age?
A new preclinical study highlights the importance of controlling new fat-cell formation to...
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
